4D Molecular Therapeutics

4D Molecular Therapeutics, headquartered at 5858 Horton St. Suite 455, Emeryville, CA 94608, specializes in developing genetic medicines through its proprietary Therapeutic Vector Evolution platform. The company focuses on ophthalmology, pulmonology, and cardiology, and has a diversified product pipeline that includes intravitreal, aerosol, and intravenous delivery methods. Key clinical products include 4D-150 for wet AMD and diabetic macular edema, 4D-125 for XLRP, 4D-110 for choroideremia, 4D-175 for geographic atrophy, 4D-710 for cystic fibrosis, and 4D-310 for Fabry disease. The company has received Fast Track Designation from the FDA for 4D-310 for the treatment of classic Fabry disease cardiomyopathy. 4D Molecular Therapeutics also collaborates with Arbor Biotechnologies to develop genetic medicines for CNS diseases and has licensed a vector to Astellas for an undisclosed rare monogenic ophthalmic disease. The company has in-house capabilities for GMP manufacturing for clinical trial material, including Phase 3 and commercial scale production, and uses directed evolution to invent customized and enhanced vectors for genetic medicines.